Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

ALNY Alnylam Pharmaceuticals Inc

233,62

-1,69 (-0,72%)

02 Jan 2025 - Fechado

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/27/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

05/10/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Kevin Fitzgerald

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Alnylam Pharmaceuticals (NASDAQ:ALNY)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Click aqui para mais gráficos Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025

Click aqui para mais gráficos Alnylam Pharmaceuticals.

Notícias Alnylam Pharmaceuticals Inc

GIVLAARI[MD] (une injection de givosiran) est maintenant remboursé au Canada pour le traitement des porphyries hépatiques aiguës (PHA) chez les adultes
Segunda, 23 de Dezembro de 2024 (2 semanas atrás) • PR Newswire (Canada)

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 13 de Dezembro de 2024 (3 semanas atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Quinta, 12 de Dezembro de 2024 (3 semanas atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 27 de Novembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 27 de Novembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 27 de Novembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 27 de Novembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 27 de Novembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Quarta, 27 de Novembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
Quarta, 27 de Novembro de 2024 (1 mês atrás) • Business Wire

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Segunda, 25 de Novembro de 2024 (1 mês atrás) • Business Wire

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
Domingo, 17 de Novembro de 2024 (2 meses atrás) • Business Wire

Mais Notícias de Alnylam Pharmaceuticals Inc

Fictor Alimentos ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições